Overview
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive form of non-Hodgkin lymphoma characterized by infiltration of the liver, spleen, and bone marrow by malignant T-cells, often presenting with systemic symptoms and multiorgan involvement 1.Diagnosis
Clinical Presentation: Malaise, abdominal distention, unintentional weight loss, and multiorgan failure 1.
Biopsy Confirmation: Essential for diagnosis; includes liver biopsy and bone marrow biopsy 1.
Imaging: May show hepatosplenomegaly; not diagnostic alone 1.
Immunophenotyping: Essential to identify T-cell origin through flow cytometry or immunohistochemistry 1.Management
First-Line Chemotherapy: Cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisolone (CHOEP regimen) 1.
Salvage Therapy: Ifosfamide, carboplatin, and etoposide (ICE regimen) for disease progression 1.
Palliative Care: Considered in cases of disease progression unresponsive to aggressive treatments 1.Special Populations
Comorbidities: Patients with inflammatory bowel disease (IBD) on TNF-α inhibitors and immunomodulators have an increased risk 2.
Age: Cases reported in elderly patients (above 65 years) and women, expanding beyond typical young male demographics 2.Key Recommendations
Biopsy Confirmation Essential for Diagnosis: Liver and bone marrow biopsies are critical for definitive diagnosis (Evidence: Strong 1).
Combine TNF-α Inhibitors with Caution in IBD: Increased risk of HSTCL in patients receiving TNF-α inhibitors alongside immunomodulators; monitor closely (Evidence: Moderate 2).
Early Aggressive Chemotherapy Recommended: Initiate first-line chemotherapy regimens like CHOEP for optimal outcomes; switch to salvage therapies like ICE for progression (Evidence: Weak 1).References
1 Pateria P, Martin A, Khor TS, Jayasekeran V. Hepatosplenic T cell lymphoma presenting as multiorgan failure. BMJ case reports 2019. link
2 Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk. European journal of gastroenterology & hepatology 2011. link